Venture Capital

After bombshell allegations and a stock plunge, Rezolve AI faces a major lawsuit investigation, raising critical questions about AI hype and corporate honesty.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

A Chinese startup's tiny new heart pump enters human trials, aiming to disrupt a billion-dollar market and solve a massive unmet need in cardiac care.

Beyond a routine board re-election, Heidmar Maritime is doubling down on an AI-driven strategy to navigate the volatile tanker market. Here's what it means.

A new report forecasts modest 2.6% growth for US construction in 2026, driven by data centers, water, and aviation, but challenged by major hurdles.

As browsers become the enterprise OS, a new security frontier emerges. Analyst firm Frost & Sullivan crowns Seraphic a leader in Zero Trust Browser Security.

As the year-long TRANSFORMERS crossover ends, we analyze the strategy, tech, and financial impact of a new benchmark in mobile gaming partnerships.

How a Defense Logistics Agency grant to 6K Energy for advanced cathode tech aims to sever risky foreign supply chains and secure America's defense.

A massive USD 300M investment in a Quebec copper foil plant is set to eliminate a critical EV battery vulnerability for North America. Here's why.

The agtech unicorn is poaching top talent from industry giants. This strategic move signals an aggressive push for global dominance in sustainable agriculture.

When a superstorm threatened a 10,000-person conference, one firm's crisis response offered a masterclass in resilience with lessons for the entire industry.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

A Minneapolis firm is testing a graft that helps the body rebuild its own arteries. This could end a painful, risky part of traditional heart bypass surgery.

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

A fintech firm's new hire seems distant, but it signals a crucial shift in how capital flows into life-saving research and healthcare innovation.

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

A decade after his passing, a hyper-exclusive David Bowie tribute redefines luxury, blending musical authenticity with bespoke hospitality for a new class of investor.

A junior miner begins a high-stakes drill program in Arizona, betting on advanced geology to find the copper essential for the world's energy transition.

A public fund's major investment in Consensys, the firm behind MetaMask, signals growing institutional confidence in Web3's foundational infrastructure.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.